China NMPA Approves Tagitanlimab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#TagitanlimabInjection #Tagitanlimab #Ketaille #NMPAApproval #NasopharyngealCancer #NPC #Immunotherapy #PDL1 #MonoclonalAntibody #KelunBiotech

Clinical Breakthrough: Phase II Study on Novel NSCLC Therapy Published in Nature Medicine Recent findings from a Phase II study reveal promising results for a novel treatment regime for advanced non-small cell lung cancer (NSCLC), combining sacituzumab tirumotecan and tagitanlimab.

Clinical Breakthrough: Phase II Study on Novel NSCLC Therapy Published in Nature Medicine #China #Chengdu #Sacituzumab #NSCLC #Tagitanlimab

Kelun-Biotech's Innovative ADC SKB315 Approved for Gastric Cancer Treatment in China Kelun-Biotech announces the approval of SKB315, a groundbreaking ADC combined with tagitanlimab, for gastric cancer treatment in China.

Kelun-Biotech's Innovative ADC SKB315 Approved for Gastric Cancer Treatment in China #China #Chengdu #Kelun-Biotech #Tagitanlimab #SKB315

Kelun-Biotech's Sac-TMT Receives Breakthrough Therapy Designation for Lung Cancer Treatment in China Sichuan Kelun-Biotech's sacituzumab tirumotecan has achieved Breakthrough Therapy Designation for non-small cell lung cancer treatment in China, emphasizing innovation.

Kelun-Biotech's Sac-TMT Receives Breakthrough Therapy Designation for Lung Cancer Treatment in China #China #Chengdu #Kelun-Biotech #Tagitanlimab #Sac-TMT

Kelun Biotech's Tagitanlimab Gains Approval for Metastatic NPC Treatment in China Kelun Biotech's innovative monoclonal antibody Tagitanlimab has received approval in China for treating metastatic nasopharyngeal cancer in combination with chemotherapy.

Kelun Biotech's Tagitanlimab Gains Approval for Metastatic NPC Treatment in China #China #Chengdu #Kelun-Biotech #Tagitanlimab #Nasopharyngeal-Cancer

Akeso Secures Payment for Tagitanlimab Development Collaboration Triumph Akeso Inc. has received payment from Sichuan Kelun Pharmaceutical for their collaboration on tagitanlimab, a PD-L1 monoclonal antibody, marking a significant achievement in oncology.

Akeso Secures Payment for Tagitanlimab Development Collaboration Triumph #Hong_Kong #Akeso_Inc #Tagitanlimab #Sichuan_Kelun